Shopping Cart
- Remove All
- Your shopping cart is currently empty
Bempegaldesleukin (NKTR-214) is a PEGylated interleukin-2 (IL-2) that functions as an immunostimulatory IL-2 proagent, acting as a CD122-preferential agonist of the IL-2 pathway. It can stimulate an antitumor immune response [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Bempegaldesleukin (NKTR-214) is a PEGylated interleukin-2 (IL-2) that functions as an immunostimulatory IL-2 proagent, acting as a CD122-preferential agonist of the IL-2 pathway. It can stimulate an antitumor immune response [1]. |
In vitro | Bempegaldesleukin is an IL-2 prodrug that has been engineered to provide controlled, sustained, and preferential signaling through the IL-2 pathway, aiming to stimulate anti-tumor immune responses while minimizing toxicity [1]. |
In vivo | Administering Bempegaldesleukin (0.8 mg/kg; i.v. for 7 days) combined with NKTR-262 significantly enhances survival rates in CD8+ T cell-dependent manner across two tumor models (CT26 and EMT6) [2]. |
Alias | NKTR-214, BEMPEG |
Cas No. | 1939126-74-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.